EW-001 Orphan Drug Designation, pre-IND update
Released
Released
Announcement PDF
1
AdAlta Limited (ASX:1AD) · ABN: 92 120 332 925 · www.adalta.com.au
Suite 1.01, 117 Camberwell Road, Hawthorn East VIC 3123, Australia
ASX Announcement | 17 November 2026
AdAlta Limited (ASX:1AD)
US FDA Orphan Drug Designation for EW-001 in mesothelioma
assigned to AdAlta
AdAlta now holds a valuable US regulatory asset for its lead CAR-T therapy,
following its first pre-IND meeting with the FDA
Investment highlights
• The US Food and Drug Administration (“FDA”) Orphan Drug Designation for EW-001 for treatment
of mesothelioma has been assigned to AdAlta by partner Shanghai Cell Therapy Group (“SHcell”).
• Orphan Drug Designation brings extended US market exclusivity after approval, waiver of FDA
application fees and other development incentives including tax credits for commercialisation partners.
• The assignment follows AdAlta’s pre-IND meeting with the FDA, which supported the potential to
use preclinical and clinical data from all prior and current manufacturing variants of EW-001 in an
IND submission.
• The constructive pre-IND meeting covered manufacturing, testing, preclinical and clinical trial design
questions, and raised no issues AdAlta had not already considered.
• Formal FDA meeting minutes are expected in early December 2026; AdAlta will update the market
once received.
Melbourne, Australia: AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next
generation cellular immunotherapies for solid cancers, today announced that Shanghai Cell Therapy Group
Co Ltd (“SHcell”) has assigned to AdAlta the US Food and Drug Administration (“FDA”) Orphan Drug
Designation (“ODD”) for EW-001 (formerly BZDS1901) in the treatment of malignant mesothelioma. EW-001
is AdAlta’s lead CAR-T cell therapy for advanced mesothelioma and other mesothelin-expressing cancers.
The assignment follows AdAlta’s first pre-IND meeting with the FDA on EW-001, held on 3 November 2026
US time (4 November 2026 AEST).
The FDA grants ODD to medicines being developed for rare diseases – those affecting fewer than 200,000
people in the United States – to encourage investment in treatments for patients with few options. SHcell,
which originally developed EW-001, first obtained the designation in February 2023. AdAlta, which holds the
rights to EW-001 outside Greater China, now holds it in its own name.
AdAlta CEO and Managing Director, Dr Tim Oldham said:
“Orphan Drug Designation is one of the most valuable regulatory assets a cancer therapy can hold in the
United States. Extended market exclusivity after approval, together with fee waivers and tax incentives,
materially strengthens the commercial case for EW-001 – for AdAlta, and for the larger biopharmaceutical
companies we expect to partner with.
Just as important is what sits behind the assignment. Our pre-IND meeting supported the potential to use the
totality of preclinical and clinical data generated across EW-001’s manufacturing variants to open our IND.
That means years of laboratory work and patient experience in China can work for us as we prepare for
clinical trials in Australia.”
2
Why Orphan Drug Designation matters
ODD does not change the evidence needed to show that EW-001 is safe and effective, but it brings significant
incentives:
• Market exclusivity. Once EW-001 is approved for malignant mesothelioma, the FDA generally cannot
approve the same medicine from a competitor for the same disease for seven years – protection that
is separate from EW-001’s patents.
• Lower costs. Exemption from the FDA’s marketing application fee (currently more than US$4 million),
and tax credits on qualifying US clinical trial costs that may benefit commercialisation partners.
• Support. Eligibility for FDA orphan product grants and FDA assistance in planning development.
Because AdAlta’s strategy is to develop products for licensing to larger biopharmaceutical companies, these
incentives add directly to what EW-001 is worth to a future partner.
Pre-IND meeting held
A pre-IND meeting lets a company test its development plan with FDA reviewers before the most expensive
work is committed. IND stands for “Investigational New Drug” – the application the FDA must accept before
clinical trials can begin under its oversight. AdAlta’s meeting covered four areas:
• Manufacturing – technology transfer from SHcell to Cell Therapies Pty Ltd (“CTPL”) in Melbourne,
and planned process optimisation.
• Testing – analytical strategies: the tests that confirm each batch of EW-001 is consistent, potent and
safe.
• Preclinical package – whether existing laboratory and animal data are suitable to support the IND,
including data from previous manufacturing variants combined with the clinical studies conducted in
China.
• Phase 1 clinical trial design – the design of AdAlta’s planned Phase 1 clinical trial in Australia.
Like many cell therapies, EW-001 has been made using successive versions of SHcell’s manufacturing
process, from the version used in the earliest clinical studies in China to the rapid, low-cost third generation
process now being transferred to CTPL. The meeting supported the potential to use the totality of
preclinical and clinical data generated across all of these variants in the IND submission.
The discussion was constructive and did not raise any FDA questions about matters or requirements that
AdAlta had not previously considered. Formal minutes reflecting the FDA’s initial feedback and the discussion
are expected in early December 2026, and AdAlta will update the market once they are received.
Next steps and strategic significance
Two near term milestones follow: the FDA’s formal pre-IND meeting minutes (expected in early December
2026) and the first manufacturing run of EW-001 in Australia at CTPL, scheduled for December 2026.
For shareholders, AdAlta now holds in its own name a US designation that strengthens EW-001’s commercial
position and appeal to partners, and the program’s first formal engagement with the FDA has gone as planned.
Both give greater confidence in the path to clinical trials of EW-001 in Australia and show the ‘East to West’
strategy working as intended.
To view a summary, and engage in discussion about this announcement visit AdAlta’s InvestorHub here:
https://investorhub.adalta.com.au/link/yanmve
This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).
For further information, please contact:
AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 403 446 665
E: ir@adalta.com.au
3
About EW-001 (formerly BZDS1901)
EW-001 (formerly BZDS1901) is a novel, first in class, CAR-T cell therapy designed to treat mesothelioma (a
rare but rapidly fatal cancer usually linked to asbestos exposure) and with possible application in more than
ten other cancers. CAR-T cell therapies are living drugs manufactured from a patient’s own immune cells
that are engineered to be able to find and kill cancer. They offer the potential to provide durable cancer
control or cure from a single treatment. EW-001 targets a protein called mesothelin that is highly expressed
in many cancers. EW-001 is also engineered to produce a checkpoint inhibitor that is designed to protect the
CAR-T cell from a key defensive mechanism used by cancers.
Patients diagnosed with mesothelioma today are typically treated with surgery if possible and then initial or
first line drug treatments are chemotherapy or immunotherapy. Once a patient has relapsed after initial
therapy, second line treatment options are even more limited and outcomes are much poorer. Current
treatments typically deliver: 1,2
• Tumour shrinkage (Overall Response) in only 40-44% of first line patients and 11-29% of second
and subsequent line patients
• Complete tumour clearance (Complete Response) is rare and seen in less than 3% of first line
patients and almost never in second line patients
• Median survival (at which point 50% of patients will have died) is often only 14-18 months for first
line and 8-10 months for second line treatment, with tumours beginning to grow again typically after
only half that time.
By contrast, EW-001 clinical studies in relapsed or advanced mesothelioma patients (second line and later)
in China have reported:
• Up to 50% Overall Response rate (tumour shrinkage)
• Up to 20% Complete Response rate (complete tumour clearance)
• Two patients achieving Complete Responses have now reached two and one year survival
milestones respectively with no evidence of cancer returning providing evidence of durability of
response
• Median overall survival has not yet been reached in the current generation manufacturing process,
however an earlier generation of EW-001 achieved more than 25 months median survival
These early results suggest EW-001 may offer an exciting potential new treatment option for patients with
few alternatives. EW-001 has not yet received regulatory approval for general commercial launch anywhere
in the world.
About AdAlta
AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular
immunotherapies for the treatment of solid cancers.
Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development
with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway
connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.
AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing
and conduct Phase I clinical studies with potential to position each product for on-licensing to larger
biopharmaceutical companies for potential registrational studies and commercialisation.
AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy
products supported by clinical data in solid cancers. The company adopts a capital efficient business model
delivering a rapid return on investment in each project that is replicable and provides opportunities to scale
across multiple products.
1
CHECKMATE-743 study (nivolumab + ipilimumab against chemotherapy): S Peters et al, Annals of Oncology, 2022 (33) 488;
https://doi.org/10.1016/j.annonc.2022.01.074
2
See for example CONFIRM study (nivolumab against placebo): DA Fennell et al, Lancet Oncol 2021 (22) 1530
4
Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies.
AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow
at a compound annual growth rate of 34% to reach US$20.3 billion by 2028.
AdAlta’s other assets include first in class fusion protein, AD-214, that takes a whole new approach to fibrotic
diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis and
WD-34, a novel pan-strain inhibitor of malaria, Babesia and Toxoplasma parasites. Following demonstration
of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is
available for partnering. WD-34 is seeking grant funding to optimise the molecule format to enable single
dose seasonal prophylaxis.
To learn more, please visit: www.adalta.com.au
For more information
Join our InvestorHub
Follow us on LinkedIn
Follow us on X (formerly Twitter)
Share your feedback
Discover